FDA Grants Priority Review for Padcev Plus Keytruda in Bladder Cancer
The FDA has granted priority review for the Padcev-Keytruda combination in untreated patients with metastatic bladder cancer, according to a news release.
Source: curetoday.com
Stay updated with breaking news from Advanced Bladder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has granted priority review for the Padcev-Keytruda combination in untreated patients with metastatic bladder cancer, according to a news release.
A phase 2 trial found that some patients with classical Hodgkin lymphoma saw a nearly 74% probability of second remission due to retreatment with Keytruda.